DK1002055T3 - Indvinding af virus fra cellekultur under anvendelse af en hypertonisk saltoplösning - Google Patents

Indvinding af virus fra cellekultur under anvendelse af en hypertonisk saltoplösning

Info

Publication number
DK1002055T3
DK1002055T3 DK98938765T DK98938765T DK1002055T3 DK 1002055 T3 DK1002055 T3 DK 1002055T3 DK 98938765 T DK98938765 T DK 98938765T DK 98938765 T DK98938765 T DK 98938765T DK 1002055 T3 DK1002055 T3 DK 1002055T3
Authority
DK
Denmark
Prior art keywords
virus
cell culture
recovery
saline solution
hypertonic saline
Prior art date
Application number
DK98938765T
Other languages
English (en)
Inventor
Michael Denis Johnston
Roderic Simon O'keeffe
Original Assignee
Xenova Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10817061&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1002055(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Xenova Res Ltd filed Critical Xenova Res Ltd
Application granted granted Critical
Publication of DK1002055T3 publication Critical patent/DK1002055T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16651—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK98938765T 1997-08-07 1998-08-07 Indvinding af virus fra cellekultur under anvendelse af en hypertonisk saltoplösning DK1002055T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9716611.0A GB9716611D0 (en) 1997-08-07 1997-08-07 Virus preparations and methods
PCT/GB1998/002387 WO1999007834A1 (en) 1997-08-07 1998-08-07 Recovery of virus from cell culture using a hypertonic salt solution
EP98938765A EP1002055B2 (en) 1997-08-07 1998-08-07 Recovery of virus from cell culture using a hypertonic salt solution

Publications (1)

Publication Number Publication Date
DK1002055T3 true DK1002055T3 (da) 2004-10-25

Family

ID=10817061

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98938765T DK1002055T3 (da) 1997-08-07 1998-08-07 Indvinding af virus fra cellekultur under anvendelse af en hypertonisk saltoplösning

Country Status (11)

Country Link
EP (1) EP1002055B2 (da)
JP (2) JP2001512675A (da)
AT (1) ATE270325T1 (da)
AU (1) AU8737298A (da)
CA (1) CA2299628A1 (da)
DE (1) DE69824856T2 (da)
DK (1) DK1002055T3 (da)
ES (1) ES2224422T3 (da)
GB (1) GB9716611D0 (da)
PT (1) PT1002055E (da)
WO (1) WO1999007834A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2460269C (en) 2001-09-06 2013-01-15 Alphavax, Inc. Alphavirus replicon vector systems
ES2552687T3 (es) * 2002-12-13 2015-12-01 Alphavax, Inc. Partículas alfavíricas y métodos de preparación
KR101518309B1 (ko) 2003-03-20 2015-05-08 알파벡스, 인크. 개선된 알파바이러스 레플리콘 및 헬퍼 구축물
CN100398642C (zh) * 2003-06-20 2008-07-02 迈克必斯生物系统公司 病毒生产的改进
MXPA05005306A (es) 2003-06-20 2005-10-26 Microbix Biosystems Inc Mejoramientos en la produccion de virus.
AU2004257214B2 (en) 2003-07-11 2010-04-22 Alphavax, Inc. Alphavirus-based cytomegalovirus vaccines
US7850977B2 (en) 2007-06-21 2010-12-14 Alphavax, Inc. Promoterless cassettes for expression of alphavirus structural proteins
SG11201503854UA (en) 2012-11-22 2015-06-29 Asahi Kasei Medical Co Ltd Method for producing parvovirus having high infectivity titer
CN104250639A (zh) * 2013-06-28 2014-12-31 北京奥源和力生物技术有限公司 一种收获和生产病毒的方法
EP3372677B8 (en) 2015-11-06 2019-09-25 Asahi Kasei Medical Co., Ltd. Method for producing parvovirus having high infectivity titer and high purity
US10626376B2 (en) 2016-11-14 2020-04-21 St. Jude Children's Research Hospital Method for isolating and purifying adeno-associated virus particles using salt
IL299723A (en) * 2020-07-10 2023-03-01 Boehringer Ingelheim Int A process for the production of purified rabies virus from cell culture

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204257A (en) * 1991-04-29 1993-04-20 Autogen Instruments, Inc. Method of recovering bacteriophage
CA2097019C (en) * 1992-06-04 2007-07-24 Philip J. Provost Process for attenuated varicella zoster virus vaccine production

Also Published As

Publication number Publication date
DE69824856D1 (de) 2004-08-05
WO1999007834A1 (en) 1999-02-18
EP1002055B1 (en) 2004-06-30
EP1002055A1 (en) 2000-05-24
ATE270325T1 (de) 2004-07-15
JP2001512675A (ja) 2001-08-28
DE69824856T2 (de) 2005-07-21
JP2009297036A (ja) 2009-12-24
AU8737298A (en) 1999-03-01
CA2299628A1 (en) 1999-02-18
PT1002055E (pt) 2004-10-29
EP1002055B2 (en) 2010-04-14
GB9716611D0 (en) 1997-10-08
ES2224422T3 (es) 2005-03-01

Similar Documents

Publication Publication Date Title
DK1002055T3 (da) Indvinding af virus fra cellekultur under anvendelse af en hypertonisk saltoplösning
CY1115749T1 (el) Κυκλοϊος χοιρων, νουκλεϊνικα οξεα, πολυπεπτιδια και εμβολια
ATE466932T1 (de) Vermehrung von viren in zellkultur
CY1106785T1 (el) Ιικα σωματιδια τα οποια απελευθερωνονται μετα απο μολυνση απο ανθρωπινο κυτταρομεγαλοϊο και η χρηση τους ως εμβολιο
EA200600582A1 (ru) Способы и композиции для лечения вирусного гепатита с
CY1114598T1 (el) Μεθοδος για την ενισχυση ενος ιου φυσαλιδωδους νοσου υπο συνθηκες ελευθερες ορου
DE60017234D1 (de) Vakzinproduktion
EA199800746A1 (ru) Способ генерации противовирусного иммунного ответа у человека или животного
ATE165345T1 (de) Sulfonsaeurederivate zur behandlung von viruserkrankungen
RU2018101139A (ru) Фармацевтические препараты для лечения вирусных инфекций глаза
EA200300215A1 (ru) Вакцинация против вирусов герпеса, ассоциированных с хозяйской клеткой
ES336810A1 (es) Un metodo para producir una cepa de celulas.
HUP0101081A2 (hu) Tápközeg és eljárás vírustenyésztésre és szaporításra
CN109223784B (zh) 小分子化合物在制备家蚕抗病毒药物中的应用
Rosso et al. A model of a cerebral tumour for studies in cancer chemotherapy
CN105255944B (zh) 基于转opn基因诱导的肝细胞体外增殖方法
ATE284709T1 (de) Virale chimären aus caev und hiv-1 genetischen elementen
CN111690688B (zh) 表达靶向REV的CRISPR/Cas9的重组马立克氏病病毒及其应用
CN105561303B (zh) 单纯疱疹病毒i型ul5基因缺失的dna疫苗的制备方法
RU2022132198A (ru) Живой аттенуированный штамм вируса желтой лихорадки, адаптированный к росту в клетках vero, и вакцинная композиция, содержащая его
ATE84722T1 (de) Tollwut-lebendimpfstoff.
RU2000125010A (ru) Способ получения бивалентной вакцины против болезни марека
TH58175A3 (th) ขั้นตอนสำหรับการเตรียมไวรัสก่อโรคมาเร็คส์โดยการใช้เซลล์สายพันธุ์เอเวียนต่อเนื่อง
EP1327687A4 (en) METHODS OF HEPATITIS C VIRUS INFECTION
RU94042470A (ru) Поливалентная вакцина для профилактики болезни марека и способ ее изготовления